Company / PP&E (Net)
Arcutis Biotherapeutics, Inc. PP&E (Net) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$1.0M
FY2025
5-year range
$1.0M / $2.3M
FY2021-FY2025
Trend
+0.2%
vs FY2024
Sector context
#157 of 193
Health Care
What the data says
Arcutis Biotherapeutics, Inc.'s pp&e (net) of $1M is lower than 81% of companies in the Health Care sector (FY2025). PP&E (Net) returned to growth in FY2025 after 3 years of decline, reaching $1M.
Based on SEC 10-K filings.
$1M in FY2025 with a 5-year CAGR of -12.3%.
Declined from $2M to $1M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -17.8%
- 5-Year CAGR
- -12.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 19% in Health CareTop 81% of 193This company $1.0M Sector average $777.6M
▼
-99.9% below sector average
Key checks
Key Insights
- 5-year CAGR of -12.3%, indicating a declining trend.
- In FY2025, pp&e (net) increased 0.2% year-over-year.
- Ranks #157 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.65 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.0M | +0.2% |
| FY2024 | $1.0M | -32.4% |
| FY2023 | $1.5M | -18.2% |
| FY2022 | $1.9M | -16.8% |
| FY2021 | $2.3M | +12.2% |
| FY2020 | $2.0M | +788.1% |
| FY2019 | $227.0K | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026